New Data Shows More Life Sciences Research Programs and Drugs Are Being Discontinued

We recently tallied six new entries for our Life Sciences Investment Tracker, identifying four more research programs and two more drugs that have been discontinued in the wake of the Inflation Reduction Act.

In January, Galapagos announced plans to "discontinue its small molecule discovery programs," including for treatments in chronic disease and immune diseases. The same month, IGM Biosciences announced layoffs and the discontinuation of two autoimmune drug candidates.

In February, Kojin Therapeutics announced that despite progress in developing first-in-class, small molecule drugs for cancer and autoimmune diseases, the company would have to wind down operations because "obtaining sufficient funding to propel these programs forward… has proven difficult to achieve."

In total, we've accounted for at least 44 research programs and 23 drugs that have been discontinued since the Inflation Reduction Act was signed into law. To learn more and see the other latest additions to our database, visit lifesciencetracker.com